acute coronary syndrome

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

anti-anginal drugs

ranolazine
MERLIN TIMI 36, 2007      NCTranolazine placeboLow risk of bias suggesting-2%

anticoagulant

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
warfarin
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative+Infini%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative+Infini%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

antiplatelets drug

not classified
Jones, 1987   dazoxibencontrolnegative
GRAND, 1987   GR3219Bcontrolnegative
Gent-AMI, 1968   misc.controlnegative
Johannessen, 1989     misc.controlnegative
French, 1993     flurbiprofenplaceboLow risk of bias suggesting-2%
CURRENT - OASIS 7 (ASA), 2010    NCTASA high doseASA low doseRisk of bias suggesting-1%-10%
aspirin
ATACS-pilot, 1990   aspirincontrolnegative
Huddinge, 1988     aspirincontrolnegative
Frankfurt, 1976   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Dutch-aspirin, 1990     aspirinplaceboLow risk of bias negative
ISIS-pilot, 1987     aspirinplaceboLow risk of bias negative-2%
ISIS-2, 1988   aspirinplaceboLow risk of bias suggesting34%
APRICOT, 1993   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar
J-LANCELOT, 2010   atopaxarplaceboExploratory -
LANCELOT ACS     atopaxarplaceboExploratory -
clopidogrel
COMMIT, 2005      NCTclopidogrelplaceboLow risk of bias suggesting
CLARITY-TIMI 28, 2005   clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
dipyridamol
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
elinogrel
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
prasugrel
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative21%-6%
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
sulfinpyrazone
Dutch sulphinpyrazone, 1986   sulfinpyrazonecontrolnegative
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
Wilcox, 1980   sulfinpyrazoneplacebonegative
Louvain sulphinpyrazone, 1983   sulfinpyrazoneplaceboLow risk of bias negative
ticagrelor
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%
ticlopidine
STAI, 1990   ticlopidinecontrolsuggesting
Knudsen-A, 1985   ticlopidinecontrolnegative
Florida UA   ticlopidineplacebonegative
trapidil
Modena   trapidilplacebosuggesting
triflusal
Plaza, 1993   triflusalplaceboLow risk of bias suggesting
vorapaxar
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -

antithrombotics

not classified
Gurfinkel (LMWH+asp vs asp), 1995     LMWHplacebo (on top of aspirin)suggesting
CURRENT - OASIS 7 (ASA), 2010    NCTASA high doseASA low doseRisk of bias suggesting-1%-10%
Gurfinkel (LMWH+asp vs UFH+asp), 1995   LMWHUFH (on top of aspirin)suggesting -100%
apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
argatroban
ARGAMI-2, 1998       Argatrobanheparin -
aspirin
ATACS-pilot, 1990   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar
LANCELOT ACS     atopaxarplaceboExploratory -
J-LANCELOT, 2010   atopaxarplaceboExploratory -
bivalirudin
ACUITY (biva alone vs hep+aGP2b3a), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsLow risk of bias suggesting-23%19%
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006    NCTbivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsLow risk of bias negative-6%13%
PROTECT-TIMI 30, 2006      NCTbivalirudineptifibatide + heparinExploratory -
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
BAT (Bittl), 1995     bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007         bivalirudinheparin + GP2b3a inhibitorssuggesting-48%19%
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007     bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative11%28%
clopidogrel
CURE (PCI sub study), 2001     clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dalteparin
FRISC (long term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias suggesting-15%
FRIC prolonged treatment phase (LWMH vs PBO), 1997     dalteparinplacebo (on top of aspirin)Low risk of bias negative61%
FRISC (short term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997     dalteparinUFH (on top of aspirin)Exploratory negative257%
dipyridamol
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
Efegatran
Klootwijk, 1999     EfegatranheparinExploratory -
enoxaparin
RESCUE    NCTenoxaparinunfractionated heparin -
EVET, 2005     enoxaparintinzaparinsuggesting-50%
ESSENCE, 1997     enoxaparinUFH (on top of aspirin)Low risk of bias suggesting -7%-3%